Related Experiment Video

Updated: May 22, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Diffuse panbronchiolitis

Shoji Kudoh1, Naoto Keicho

  • 1Japan Anti-Tuberculosis Association, Fukujuji Hospital, Kiyose, Tokyo, Japan. kudous@fukujuji.org

Clinics in Chest Medicine
|May 30, 2012
PubMed

Insights

Diffuse panbronchiolitis (DPB), a chronic airway disease prevalent in East Asians, shows improved outcomes with long-term, low-dose macrolide therapy. This treatment leverages macrolides' anti-inflammatory properties, offering new hope for managing DPB and similar inflammatory airway conditions.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Diffuse panbronchiolitis (DPB) is a chronic airway infection causing diffuse bilateral micronodular pulmonary lesions.
  • DPB predominantly affects East Asian populations, suggesting a unique genetic predisposition.
  • Traditional treatments have limited efficacy in altering the disease's natural course.

Purpose of the Study:

  • To investigate the efficacy of low-dose, long-term macrolide therapy in managing Diffuse Panbronchiolitis.
  • To explore the anti-inflammatory mechanisms of macrolides in the context of DPB.
  • To assess the potential of macrolide therapy for other chronic airway inflammatory diseases.

Main Methods:

  • Review of studies on the genetic predisposition and epidemiological distribution of DPB.
  • Analysis of clinical data on the outcomes of low-dose, long-term macrolide therapy in DPB patients.
  • Examination of the pharmacological mechanisms of 14-membered and 15-membered ring macrolides.

Main Results:

  • Low-dose, long-term macrolide therapy has significantly improved the prognosis of Diffuse Panbronchiolitis.
  • The therapeutic effect is attributed to the potent anti-inflammatory actions of macrolides.
  • Successful application in DPB suggests broader utility in other chronic airway inflammatory conditions.

Conclusions:

  • Macrolide therapy represents a breakthrough in managing Diffuse Panbronchiolitis, particularly in Asian populations.
  • The anti-inflammatory effects of macrolides offer a novel therapeutic strategy for chronic airway inflammation.
  • Further research into macrolide applications for related respiratory diseases is warranted.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...